In 2023, the Reagan-Udall Foundation published plans for a public private partnership with industry to voluntarily collect data on the use of antimicrobials in farm animals.

Zeroing in on what is needed to improve operations, including the PMTA process, Booth said a review of the Reagan-Udall Foundation report is critical.

In addition to the new AACR award, Dr. Pazdur has received numerous awards and honors throughout his career: the Regulatory Affairs Professionals Society Patient-Centered Health Award (2021), the University of Chicago Cancer Research Foundation Simon M. Shubitz Cancer Prize and Lectureship (2020), the FDA Alumni Association Harvey W. Wiley Award (2019), recognition as one of OncLive’s Giants of Cancer Care (2019), the Reagan-Udall Foundation Innovations in Regulatory Science Award for Leadership (2018)...

In 2022, the FDA requested the Reagan Udall Foundation conduct an independent investigation of the CTP. The resulting report highlighted several shortcomings, including a lack of a clear regulatory and product approval framework, an inefficient and slow product review process, a lack of transparency and communication, and broad struggles with the vaping market.

Regulatory agencies need access to external experts in order to improve regulatory processes, scan the horizon for emerging technologies, and engage with the public, among other activities. Government-affiliated foundations provide a flexible and efficient way to supplement federal activities. Examples include the Reagan-Udall Foundation for the FDA…

The FDA’s recent reorganization illustrates the value of transparency—radical or otherwise—to industry and consumers alike. In the wake of an infant formula crisis that justifiably incensed the public and lawmakers, the agency relied on extensive hearings, culminating in an expert report commissioned by the Reagan-Udall Foundation.

The failures of the CTP are well-documented. In 2022, an independent review by the Reagan-Udall Foundation found that the agency was in disarray, manipulated by outside interests rather than driven by scientific evidence.

A 2022 report by the Reagan-Udall Foundation concluded that the CTP had failed in its primary role as a product regulator.

On 4 September 2024, the Reagan-Udall Foundation for the FDA (FDA Foundation) in collaboration with the Food and Drug Administration (FDA) and the Gates Foundation hosted a workshop titled “Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence”.

A December 2022 report by the Reagan-Udall Foundation found the CTP had failed in its primary mission to regulate.